Omega Pharma's 2008 net profit jumps 19%

23 March 2009

Belgian company Omega Pharma says its 2008 net profit grew 19% year-on-year to 50.8 million euros ($66.0 million), rising to 66.4  million euros after addition of 24% of the net income of its health care  supplies affiliate Arseus.

The firm, which is one of the few major players in its sector that deals  exclusively in over-the-counter products, says net turnover rose 3% to  811.2 million euros, as its operating cash flow jumped 4% to 130.1  million euros.

Earnings before interest, taxes, depreciation and amortization in its  home market soared 26% to 29.7 million euros on the back of a 3% rise in  turnover to 205.0 million euros. This corresponds to a 14.5% EBITDA  margin versus 11.9% in 2007, thanks to restructurings and the increase  efficiency of its domestic operations. However, EBITDA in France fell 8%  to 19.4 million euros, as revenues dropped 2% to 187.4 million euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight